The appeal to investors of these companies may in some cases not be immediate, but patient investors may be rewarded. And one last thought, the Street is always worried about sales and earnings, and for the larger capped biotechs that model can apply. But for the smaller ones, the concern by the Street is sustainable business models, companies who have a solid management team, cash and technological platform. Often times, the Street may not have a firm understanding of what biotechnology is striving for which can lead to inefficient stock evaluations, thus for individual investors it can represent an opportunity, but for investors you will have to do your homework. Such Information is neither an offer to sell nor a solicitation to buy the securities of any company.
Additional information is available upon request.
Information in this publication has been obtained from sources believed to be reliable, but the accuracy, completeness and interpretation are not guaranteed. Opinions expressed are subject to change without notice. The Information is supplied on the condition that the reader or any other person receiving the Information will make his or her own determination as to its suitability for any purpose prior to any use of the Information. This report may not be reproduced, distributed or published by any recipient for any purpose without the prior express consent of the publishers. Changes in rates of currency exchange may have an adverse effect on the value, price or income of investments.